Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Fengxiang Huang
Haiyan Yang
Wenguang Bao
Yehong Bin
Shengsheng Zhou
Man Wang
Xiaoping Lv
机构：
[1] The First Affiliated Hospital of Guangxi Medical University,Department of Oncology
[2] The First Affiliated Hospital of Guangxi Medical University,Department of Gastroenterology
来源：
Clinical and Translational Oncology | 2024年 / 26卷
关键词：
Metastatic colorectal cancer; TAS-102; Efficacy; Safety; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：468 / 476
页数：8
相关论文
共 50 条
  • [11] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Daisuke Kotani
    Yasutoshi Kuboki
    Satoshi Horasawa
    Asumi Kaneko
    Yoshiaki Nakamura
    Akihito Kawazoe
    Hideaki Bando
    Hiroya Taniguchi
    Kohei Shitara
    Takashi Kojima
    Akihito Tsuji
    Takayuki Yoshino
    BMC Cancer, 19
  • [12] Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis.
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    Berry, Scott R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [13] A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer
    Sonbol, Mohamad Bassam
    Benkhadra, Raed
    Wang, Zhen
    Firwana, Belal
    Walden, Daniel J.
    Mody, Kabir
    Hubbard, Joleen M.
    Murad, M. Hassan
    Ahn, Daniel H.
    Bekaii-Saab, Tanios
    ONCOLOGIST, 2019, 24 (09): : 1174 - 1179
  • [14] A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis
    Abrahao, Ana B. K.
    Ko, Yoo-Joung
    Berry, Scott
    Chan, Kelvin K. W.
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 113 - 120
  • [15] Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102)
    Falcone, A.
    Ohtsu, A.
    Van Cutsem, E.
    Mayer, R.
    Buscaglia, M.
    Bendell, J. C.
    Kopetz, S.
    Wahba, M.
    Bebeau, P.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [16] Safety of trifluridine/tipiracil (TAS-102) in combination with temozolomide for metastatic neuroendocrine tumors.
    Uboha, Nataliya Volodymyrivna
    Deming, Dustin A.
    Lubner, Sam Joseph
    Mulkerin, Daniel
    Eickhoff, Jens C.
    LoConte, Noelle K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [17] Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: a real-life overview
    Salvatore, L.
    Niger, M.
    Bellu, L.
    Tamburini, E.
    Garcia-Alfonso, P.
    Amellal, N.
    Delmas, A-S.
    Wahba, M.
    Prager, G.
    ANNALS OF ONCOLOGY, 2016, 27
  • [18] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
    C. Carriles
    P. Jimenez-Fonseca
    M. Sánchez-Cánovas
    P. Pimentel
    A. Carmona-Bayonas
    T. García
    M. Carbajales-Álvarez
    A. Lozano-Blázquez
    Clinical and Translational Oncology, 2019, 21 : 1781 - 1785
  • [19] Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
    Yoshino, Takayuki
    Taieb, Julien
    Kuboki, Yasutoshi
    Pfeiffer, Per
    Kumar, Amit
    Hochster, Howard S. S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [20] Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status
    Carriles, C.
    Jimenez-Fonseca, P.
    Sanchez-Canovas, M.
    Pimentel, P.
    Carmona-Bayonas, A.
    Garcia, T.
    Carbajales-Alvarez, M.
    Lozano-Blazquez, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (12): : 1781 - 1785
12345